Form 4: Richard Berman Receives Stock Option Grant from Celularity Inc

Director Richard J Berman received a stock option grant from Celularity Inc on August 27, 2024.

Summary

• Richard J Berman, a director of Celularity Inc, was granted a stock option on August 27, 2024.
• The option allows Berman to purchase 118,111 shares of Class A Common Stock at an exercise price of $3.01.
• The option was granted under the Issuer's 2021 Equity Incentive Plan.
• The shares will vest in three equal annual installments from the grant date, contingent upon Berman's continued service with Celularity.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral-to-positive event.

Positives

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common practice in the corporate world to incentivize and retain key personnel, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• The vesting schedule of three years is typical for such grants.
• Comparable companies such as CRISPR Therapeutics and Beam Therapeutics also utilize stock options as part of their compensation strategy.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates